Resmed Inc Intrinsic Value Calculation – Pathstone Family Office LLC Increases Stake in ResMed by 98.8% in 2023.
March 14, 2023
Trending News 🌥️
RESMED ($NYSE:RMD): In the third quarter of 2023, Pathstone Family Office LLC significantly increased its stake in ResMed Inc, a leading global medical technology company, by 98.8 percent. The move further solidifies Pathstone Family Office LLC’s investment in ResMed Inc., which manufactures and distributes a broad range of products and solutions designed to improve the quality of life for individuals with chronic or acute respiratory conditions. ResMed’s products include airway pressure devices, humidification systems, masks, headgear, and software solutions to provide patients with access to personalized therapy choices. Pathstone’s confidence in ResMed is further bolstered by the company’s strong financial performance in recent years, with rising revenues, earnings, and cash flows.
As a result, investors have responded positively to the news of the latest increase in stake; ResMed Inc’s stocks have risen since the news was announced. It is clear that Pathstone Family Office LLC has a strong belief in the potential of ResMed and its ability to continue to innovate and provide quality products and services to its customers. Given their substantial increase in stake, it appears that Pathstone is confident in ResMed’s future prospects and will continue to invest heavily in the company for the long term.
Share Price
Currently, news coverage is mostly positive surrounding the company and its stock performance. On Monday, RESMED INC stock opened at $205.2 and closed at $206.3, up by 0.2% from prior closing price of 205.9. This increase in stock price reflects the market’s growing confidence in the company’s future prospects and financial health. It will be interesting to see how the stock performs in the coming weeks and months, as investors continue to watch the company’s progress. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Resmed Inc. More…
| Total Revenues | Net Income | Net Margin |
| 3.76k | 809.47 | 21.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Resmed Inc. More…
| Operations | Investing | Financing |
| 370.22 | -1.19k | 887.66 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Resmed Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.68k | 2.94k | 23.44 |
Key Ratios Snapshot
Some of the financial key ratios for Resmed Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.6% | 14.8% | 28.0% |
| FCF Margin | ROE | ROA |
| 5.9% | 18.4% | 9.9% |
Analysis – Resmed Inc Intrinsic Value Calculation
At GoodWhale, we recently conducted an analysis of the fundamentals of RESMED INC. After extensive research, our proprietary Valuation Line was used to calculate the intrinsic value of RESMED INC’s shares, coming to a total of approximately $240.2. However, at present, the stock is being traded at $206.3, creating an opportunity for investors, as the stock is currently undervalued by 14.1%. More…
Peers
ResMed’s competitors include Natus Medical Inc, Sanara MedTech Inc, and Avita Corp.
– Natus Medical Inc ($NASDAQ:SMTI)
As of 2022, Sanara MedTech Inc has a market cap of 227.36M and a Return on Equity of -22.91%. The company is a medical device company that develops and manufactures products for the treatment of chronic wounds and other conditions.
– Sanara MedTech Inc ($TPEX:4735)
Avita Corp is a biotechnology company that develops, manufactures, and markets products based on regenerative medicine. The company’s products are used to treat a variety of conditions, including burns, wounds, and skin diseases. Avita’s products are sold in over 30 countries worldwide. The company has a market cap of 1.21B as of 2022 and a return on equity of 9.62%.
Summary
ResMed Inc. has seen a significant increase in investment by Pathstone Family Office LLC in 2023. According to news coverage, the majority of the sentiment around the move is positive. From an investing perspective, ResMed Inc. is an attractive option for investors due to its strong fundamentals and resilience during volatile markets.
ResMed Inc.’s growth potential is further bolstered by its strong product portfolio and innovative research and development initiatives. Taking all these factors into account, ResMed Inc. appears to be a promising long-term investment opportunity.
